serve as an urgent call to action.(1, 2) As rheumatologists, we are acutely aware of the higher morbidity and mortality, and for a number of our diseases, the higher incidence and prevalence among racial/ethnic minorities and individuals of lower socioeconomic status (SES).(3-6) Comorbidities are frequent, timely access to subspecialty care is limited, receipt of high quality care is less common, and care is more often fragmented with frequent, avoidable acute care use.(7, 8) Among patients with systemic lupus erythematosus (SLE) where these disparities have been shown to be particularly pronounced, prolonged glucocorticoid use and delayed or lack of standard-of-care immunosuppressive use is common, and hydroxychloroquine, the backbone of SLE therapy to prevent flares and organ damage, is under-prescribed and adherence is suboptimal.(9) In addition, despite at least two-tothree-fold higher prevalence of SLE and significantly poorer outcomes, black individuals compared to white, are much less likely to be enrolled in clinical trials.(10, 11) Structural racism, historical Accepted Article